In this video, you will explore more about how Mounjaro (Tirezapetide) helped people with Type 2 Diabetes Mellitus in SURPASS-3 Trail.
SURPASS-3: a 52-weeks, randomized, open-label, phase 3 trial, comparing Mounjaro vs Insulin Degludec 100 U/ml in 1444 adults with T2DM inadequately controlled on metformin with or without SGLT-2.
This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
For adverse events and safety reporting, please send an email: [email protected]
For further information, please contact: Eli Lilly and Company, Scientific office O.O Box 92120
Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800
Please go to PDF Material for prescribing information.